Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + enzalutamide as first-line therapy for HER2-expressing mCRPC (Phase II, single-arm)
ChiCTR2600124058Phase 2Not yet recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in prostate cancer (PCa), sponsored by Yantai Yuhuangding Hospital. Primary endpoint: PSA50 response rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2600124058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124058.